| 臺大學術典藏 |
2022-09-15T01:08:50Z |
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trial
|
Patnaik A.; Yap T.A.; Chung H.C.; de Miguel M.J.; Bang Y.-J.; Chia-Chi Lin; Su W.-C.; Italiano A.; Chow K.H.; Szpurka A.M.; Yu D.; Zhao Y.; Carlsen M.; Schmidt S.; Vangerow B.; Gandhi L.; Xu X.; Bendell J. |
| 臺大學術典藏 |
2022-09-15T01:08:51Z |
Fibroblast Growth Factor Receptor Inhibitors Reduce Adipogenesis of Orbital Fibroblasts and Enhance Myofibroblastic Differentiation in Graves’ Orbitopathy
|
Shih S.-R.; Liao S.-L.; Shih C.-W.; Wei Y.-H.; Lu T.-X.; Chou C.-H.; Yen E.-Y.; Chang Y.-C.; Chia-Chi Lin; Chi Y.-C.; Yang W.-S.; Tsai F.-C. |
| 臺大學術典藏 |
2022-09-15T01:08:51Z |
Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study
|
Chia-Chi Lin; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; Hsu C. |
| 臺大學術典藏 |
2022-09-15T01:08:51Z |
Clinical development of colony-stimulating factor 1 receptor (Csf1r) inhibitors
|
Chia-Chi Lin |
| 臺大學術典藏 |
2022-09-15T01:08:52Z |
An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer
|
Bible K.C.; Menefee M.E.; Chia-Chi Lin; Millward M.J.; Maples W.J.; Goh B.C.; Karlin N.J.; Kane M.A.; Adkins D.R.; Molina J.R.; Donehower R.C.; Lim W.-T.; Flynn P.J.; Richardson R.L.; Traynor A.M.; Rubin J.; Lorusso P.M.; Smallridge R.C.; Burton J.K.; Suman V.J.; Kumar A.; Voss J.S.; Rumilla K.M.; Kipp B.R.; Chintakuntlawar A.V.; Harris P.; Erlichman C. |
| 臺大學術典藏 |
2022-09-15T01:08:52Z |
Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
|
Bang Y.-J.; Golan T.; Dahan L.; Fu S.; Moreno V.; Park K.; Geva R.; De Braud F.; Wainberg Z.A.; Reck M.; Goff L.; Laing N.; Mi G.; Oliveira J.M.; Wasserstrom H.; Chia-Chi Lin |
| 臺大學術典藏 |
2022-09-15T01:08:53Z |
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC
|
Zhu V.W.; Lin Y.-T.; Kim D.-W.; Loong H.H.; Nagasaka M.; To H.; Ang Y.L.-E.; Ock C.-Y.; Tchekmedyian N.; Ou S.-H.I.; Syn N.L.; Reungwetwattana T.; Chia-Chi Lin; Soo R.A. |
| 臺大學術典藏 |
2022-09-15T01:08:53Z |
PD-1 blockade in anaplastic thyroid carcinoma
|
Capdevila J.; Wirth L.J.; Ernst T.; Aix S.P.; Chia-Chi Lin; Ramlau R.; Butler M.O.; Delord J.-P.; Gelderblom H.; Ascierto P.A.; Fasolo A.; F?hrer D.; H?tter-Kr?nke M.L.; Forde P.M.; Wrona A.; Santoro A.; Sadow P.M.; Szpakowski S.; Wu H.; Bostel G.; Faris J.; Cameron S.; Varga A.; Taylor M. |
| 臺大學術典藏 |
2022-09-15T01:08:54Z |
Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma
|
Si L.; Zhang X.; Shin S.J.; Fan Y.; Chia-Chi Lin; Kim T.M.; Dechaphunkul A.; Maneechavakajorn J.; Wong C.S.; Ilankumaran P.; Lee D.-Y.; Gasal E.; Li H.; Guo J. |
| 臺大學術典藏 |
2022-09-15T01:08:54Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Chia-Chi Lin; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-09-15T01:08:55Z |
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial
|
Paz-Ares L.; Kim T.M.; Vicente D.; Felip E.; Lee D.H.; Lee K.H.; Chia-Chi Lin; Flor M.J.; Di Nicola M.; Alvarez R.M.; Dussault I.; Helwig C.; Ojalvo L.S.; Gulley J.L.; Cho B.C. |
| 臺大學術典藏 |
2022-09-15T01:08:56Z |
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
|
Desai J.; Deva S.; Lee J.S.; Chia-Chi Lin; Yen C.-J.; Chao Y.; Keam B.; Jameson M.; Hou M.-M.; Kang Y.-K.; Markman B.; Lu C.-H.; Rau K.-M.; Lee K.-H.; Horvath L.; Friedlander M.; Hill A.; Sandhu S.; Barlow P.; Wu C.-Y.; Zhang Y.; Liang L.; Wu J.; Paton V.; Millward M. |
| 臺大學術典藏 |
2022-09-15T01:08:57Z |
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
|
Peters S.; Shaw A.T.; Besse B.; Felip E.; Solomon B.J.; Soo R.A.; Bearz A.; Gadgeel S.M.; Chia-Chi Lin; Kao S.; Seto T.; Masters E.T.; Abbattista A.; Clancy J.S.; Thurm H.; Reisman A.; Peltz G.; Ross Camidge D. |
| 臺大學術典藏 |
2022-09-15T01:08:57Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Chia-Chi Lin; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; Lee J.-H.; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L. |
| 臺大學術典藏 |
2022-09-15T01:08:57Z |
Phase I dose-escalation and -expansion study of telisotuzumab (ABT-700), an Anti-c-met antibody, in patients with advanced solid tumors
|
Strickler J.H.; LoRusso P.; Salgia R.; Kang Y.-K.; Yen C.J.; Chia-Chi Lin; Ansell P.; Motwani M.; Wong S.; Yue H.; Wang L.; Reilly E.; Afar D.; Naumovski L.; Ramanathan R.K. |
| 臺大學術典藏 |
2022-09-15T01:08:58Z |
A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies
|
Yamamoto N.; Ryoo B.-Y.; Keam B.; Kudo M.; Chia-Chi Lin; Kunieda F.; Ball H.A.; Moran D.; Komatsu K.; Takeda K.; Fukuda M.; Furuse J.; Morita S.; Doi T. |
| 臺大學術典藏 |
2022-09-15T01:08:59Z |
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors
|
Naing A.; Gainor J.F.; Gelderblom H.; Forde P.M.; Butler M.O.; Chia-Chi Lin; Sharma S.; Ochoa De Olza M.; Varga A.; Taylor M.; Schellens J.H.M.; Wu H.; Sun H.; Silva A.P.; Faris J.; Mataraza J.; Cameron S.; Bauer T.M. |
| 臺大學術典藏 |
2022-09-15T01:08:59Z |
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
|
Tan W.L.; Chua K.L.M.; Chia-Chi Lin; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; Yang J.C.; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F. |
| 臺大學術典藏 |
2022-09-15T01:09:00Z |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|
Drilon A.; Siena S.; Dziadziuszko R.; Barlesi F.; Krebs M.G.; Shaw A.T.; de Braud F.; Rolfo C.; Ahn M.-J.; Wolf J.; Seto T.; Cho B.C.; Patel M.R.; Chiu C.-H.; John T.; Goto K.; Karapetis C.S.; Arkenau H.-T.; Kim S.-W.; Ohe Y.; Li Y.-C.; Chae Y.K.; Chung C.H.; Otterson G.A.; Murakami H.; Chia-Chi Lin; Tan D.S.W.; Prenen H.; Riehl T.; Chow-Maneval E.; Simmons B.; Cui N.; Johnson A.; Eng S.; Wilson T.R.; Doebele R.C. |
| 臺大學術典藏 |
2022-09-15T01:09:00Z |
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts
|
Bang Y.-J.; Su W.-C.; Schuler M.; Nam D.-H.; Lim W.T.; Bauer T.M.; Azaro A.; Poon R.T.P.; Hong D.; Chia-Chi Lin; Akimov M.; Ghebremariam S.; Zhao S.; Giovannini M.; Ma B. |
| 臺大學術典藏 |
2022-09-15T01:09:01Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Lee J.-H.; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; Cheng A.-L.; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Chia-Chi Lin |
| 臺大學術典藏 |
2022-09-15T01:09:01Z |
Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial
|
Drakaki A.; Kirby C.J.; Van Der Heijden M.S.; Petrylak D.P.; Powles T.; Chi K.N.; Fl?chon A.; Necchi A.; G?czi L.; Lee J.-L.; Gakis G.; Bracarda S.; Chowdhury S.; Chia-Chi Lin; Keizman D.; Vaishampayan U.N.; Zimmermann A.H.; Bell-Mcguinn K.; Castellano D. |
| 臺大學術典藏 |
2022-09-15T01:09:02Z |
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
|
Petrylak D.P.; de Wit R.; Chi K.N.; Drakaki A.; Sternberg C.N.; Nishiyama H.; Castellano D.; Hussain S.A.; Fl?chon A.; Bamias A.; Yu E.Y.; van der Heijden M.S.; Matsubara N.; Alekseev B.; Necchi A.; G?czi L.; Ou Y.-C.; Coskun H.S.; Su W.-P.; Bedke J.; Gakis G.; Percent I.J.; Lee J.-L.; Tucci M.; Semenov A.; Laestadius F.; Peer A.; Tortora G.; Safina S.; Garcia del Muro X.; Rodriguez-Vida A.; Cicin I.; Harputluoglu H.; Tagawa S.T.; Vaishampayan U.; Aragon-Ching J.B.; Hamid O.; Liepa A.M.; Wijayawardana S.; Russo F.; Walgren R.A.; Zimmermann A.H.; Hozak R.R.; Bell-McGuinn K.M.; Powles T.; Wong S.-L.S.; Tan T.H.; Hovey E.J.; Clay T.D.; Wan Ng S.S.; Rutten A.; Machiels J.-P.; Dumez H.; Cheng S.Y.-S.; Ferrario C.; Sengeloev L.; Jensen N.V.; Thibault C.; Laguerre B.; Joly F.; Culine S.; Becht C.; Niegisch G.; St?ckle M.; Grimm M.-O.; Schwentner C.A.; Schultze-Seemann W.; Kalofonos H.; Mavroudis D.; Papandreou C.; Karavasilis V.; R?v?sz J.; Rosenbaum E.; Leibowitz-Amit R.; Kejzman D.; Sarid D.; Scagliotti G.V.; Bracarda S.; Massari F.; Osawa T.; Miyajima N.; Shinohara N.; Fukuta F.; Ohyama C.; Obara W.; Yamashita S.; Tomita Y.; Kawai K.; Fukasawa S.; Oyama M.; Yonese J.; Nagata M.; Uemura M.; Nishimura K.; Kawakita M.; Tsunemori H.; Hashine K.; Inokuchi J.; Yokomizo A.; Nagamori S.; Lee H.J.; Park S.H.; Rha S.Y.; Kim Y.J.; Lee Y.-G.; Vazquez Cort?s L.; Lorena Urzua Flores C.; Blaisse R.J.B.; Erdkamp F.L.G.; Aarts M.J.B.; Wojcik-Tomaszewska J.; Tomczak P.; Sikora-Kupis B.; Schenker M.; Herzal A.A.; Udrea A.A.; Karlov P.; Fomkin R.; Gajate Borau P.; Grande E.; Delgado Mignorance J.I.; Su Y.-L.; Li J.-R.; Lin C.-L.; Chia-Chi Lin; Yeh S.-P.; Erman M.; Urun Y.; Golovko Y.; Bondarenko I.; Sinielnikov I.; Crabb S.J.; Syndikus I.; Huddart R.; Sundar S.; Chowdhury S.; Sarwar N.; Flaig T.W.; Pan C.X.; Schwarz J.K.; Cultrera J.L.; Acs P.I.; Hainsworth J.D.; Herms B.T.; Lawler W.E.; Lowe T.E. |
| 臺大學術典藏 |
2022-09-15T01:09:03Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Chia-Chi Lin; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-09-15T01:09:04Z |
Nuclear factor-κB overexpression is correlated with poor outcomes after multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer
|
Chiang Y.; Wang C.-C.; Tsai Y.-C.; Huang C.-Y.; Pu Y.-S.; Chia-Chi Lin; Cheng J.C.-H. |
